Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FABULOUS: Treatment-Free Interval in Newly Diagnosed Multiple Myeloma
NCT06187441Phase 3Recruiting
- Sponsor
- HOVON
- Start
- May 2024
- Primary completion
- Jan 2031
- Modality
- Monoclonal Antibodies, Recombinant Proteins and Enzymes, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 3 trial of daratumumab, lenalidomide, dexamethasone in multiple myeloma (MM), sponsored by HOVON. Started May 2024; status: recruiting.
02
Drugs
daratumumablenalidomidedexamethasone
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT06187441.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06187441.